Endocrine influences on human mammary cancer formationa critique
1969; Wiley; Volume: 23; Issue: 4 Linguagem: Inglês
10.1002/1097-0142(196904)23
ISSN1097-0142
Autores Tópico(s)Estrogen and related hormone effects
ResumoCancerVolume 23, Issue 4 p. 781-790 ArticleFree Access Endocrine influences on human mammary cancer formation a critique Henry M. Lemon MD, FACP, Henry M. Lemon MD, FACP Dept. of Internal Medicine, Univ. of Nebraska College of Medicine, Omaha, Neb.Search for more papers by this author Henry M. Lemon MD, FACP, Henry M. Lemon MD, FACP Dept. of Internal Medicine, Univ. of Nebraska College of Medicine, Omaha, Neb.Search for more papers by this author First published: April 1969 https://doi.org/10.1002/1097-0142(196904)23:4 3.0.CO;2-1Citations: 53AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Abstract The possible relationship of abnormal C18 and C19 steroid excretions to fibrocystic disease and to carcinoma of the human female breast has been reviewed in relation to newer knowledge of estrogen receptor sites in uterine and mammary tissues. Proteins from these receptors exhibit different binding affinities for C18 and C19 steroids, with none of the latter exhibiting competitive binding. Within the C18 (estrogen) series, estriol inhibits competitively the uterotropic activity of estradiol 17B, displaces estradiol from uterine receptor proteins and thus far is not reported to be carcinogenic for the breast. Subnormal excretion of the C19 steriods androsterone and etiocholanolone relative to 17–hydroxycorticosteroids has been reported in chronic bronchial asthma and in untreated cancer of the breast but not thus far in premenopausal Caucasian women with fibrocystic mammary disease. Earlier reports of normal and increased estriol excretion in untreated mammary cancer compared with matched controls have not been confirmed by 3 recent investigations, in which fibrocystic disease alone, fibrocystic disease plus untreated mammary cancer and premenopausal or postmenopausal mammary cancer patients excreted subnormal estriol relative to estrone or estradiol. Hyperthyroidism is the only nonneoplastic syndrome reported thus far besides fibrocystic disease or cancer with reduced estriol quotients, but up to one fifth of euthyroid premenopausal women without mammary disease may excrete subnormal estriol quotients. Stress, tissue anoxia, ACTH therapy, pregnancy, hypothyroidism, obesity, castration and menopause normally increase the rate of estriol excretion relative to other estrogens and must be considered in future investigations needed to elucidate the divergent results reported for C18 steroid excretion in this disease. References 1 Allen, B. J., Hayward, J. L., and Merivale, W. H. H.: The excretion of 17 oxo-steroids in the urine of patients with generalized carcinomatosis secondary to carcinoma of the breast. In Endocrine Aspects of Breast Cancer, A. R. Currie ed. Livingstone, Edinburgh and London, 1958; pp. 253–262. Google Scholar 2 Bacigalupo, G., and Schubert, K.: Untersuchungen uber die oestrogen auscheidung im urin bei mastopathie. Klin. Wochschr. 38: 804–805, 1960. 10.1007/BF01487755 CASPubMedWeb of Science®Google Scholar 3 Bacigalupo, G., and Schubert, K.: Some aspects of oestrogen metabolism in cases of human mammary neoplasia. Europ. J. Cancer 2: 75–83, 1966. 10.1016/0014-2964(66)90092-2 CASPubMedGoogle Scholar 4 Barker, K. L., and Anderson, J. M.: Displacement of estradiol 17B from the uterus by estradiol 17 a. Effect on template capacity of uterine chromatin. To be submitted for publication. Google Scholar 5 Barlow, J. J.: Adrenocortical influences on estrogen metabolism of normal females. J. Clin. Endocr. 24: 586–596, 1964. 10.1210/jcem-24-7-586 CASPubMedWeb of Science®Google Scholar 6 Barlow, J. J., and Logan, C. M.: Estrogen secretion, biosynthesis and metabolism. Their relationship to the menstrual cycle. Steroids 7: 309–320, 1966. 10.1016/0039-128X(66)90102-4 CASPubMedWeb of Science®Google Scholar 7 Bauld, W. S., Givner, M. L., and Milne, I. G.: Abnormality of estrogen metabolism in human subjects with myocardial infarction. Canad. J. Biochem. Physiol. 35: 1277–1288, 1957. 10.1139/o57-146 CASPubMedWeb of Science®Google Scholar 8 Borglin, N. E., and Rappe, A.: Effect of estriol on breast engorgement and lactation in non-nursing mothers. Amer. J. Obstet. Gynec. 81: 335–338, 1961. 10.1016/S0002-9378(16)36374-8 Web of Science®Google Scholar 9 Brecher, P. I., and Wotiz, H. H.: Competition between estradiol and estriol for end organ receptor proteins. Steroids 9: 431–442, 1967. 10.1016/0039-128X(67)90030-X CASPubMedWeb of Science®Google Scholar 10 Brown, J. B.: Urinary oestrogen excretion in the study of mammary cancer. In Endocrine Aspects of Breast Cancer, A. R. Currie ed. Livingstone, Edinburgh and London, 1958; pp. 197–208. Google Scholar 11 Brown, J. B., and Mathew, G. D.: Urinary estrogen measurements and gynecology. Recent Prog. Horm. Res. 18: 337, 1962. Web of Science®Google Scholar 12 Brown, J. B., and Strong, J. A.: The effect of nutritional status and thyroid function on the metabolism of oestradiol. J. Endocr. 32: 107–115, 1965. 10.1677/joe.0.0320107 CASPubMedWeb of Science®Google Scholar 13 Bulbrook, R. D.: Hormone assays in human breast cancer. Vitam. and Horm. 23: 329–357, 1967. 10.1016/S0083-6729(08)60384-2 Google Scholar 14 Bulbrook, R. D., Thomas, B. S., Utsonomiya, J., and Hamaguchi, E.: The urinary excretion of 11-deoxy-17-oxosteroids and 17-hydroxy-corticosteroids by normal Japanese and British women. J. Endocr. 38: 401–406, 1967. 10.1677/joe.0.0380401 CASPubMedWeb of Science®Google Scholar 15 Bulbrook, R. D., and Hayward, J. L.: Abnormal urinary steroid excretion and subsequent breast cancer: A prospective study in the island of Guernsey. Lancet 1: 519–522, 1967. 10.1016/S0140-6736(67)92107-1 PubMedWeb of Science®Google Scholar 16 Burns, E. L., and Schenken, J. R.: Quantitative studies on the relationship between estrogen and mammary gland carcinoma in strain C3H mice. Proc. Soc. Exp. Biol. Med. 43: 608–610, 1940. 10.3181/00379727-43-11279 CASWeb of Science®Google Scholar 17 Clayson, D. B.: Tumors induced by hormones without other added carcinogenic stimuli. In Chemical Carcinogenesis. Boston, Little, Brown & Company, 1962; pp. 315–346. Google Scholar 18 Clemmeson, J.: Statistical Studies in Malignant Neoplasms. I. Review and Results. Munksgaard, Kobenhavn, 1965; pp. 249–271. Google Scholar 19 Crowley, L. G., Demetriou, J. A., Kotin, P., Donovan, A. J., and Kushinsky, S.: Excretion patterns of urinary metabolites of estradiol-4-C14 in post-menopausal women with benign and malignant disease of the breast. Cancer Res. 25: 371–376, 1965. CASPubMedWeb of Science®Google Scholar 20 Deshpande, N., Jensen, V., Bulbrook, R. D., Berne, T., and Ellis, F.: Accumulation of tritiated oestradiol by human breast tissue. Steroids 10: 219–232, 1967. 10.1016/0039-128X(67)90049-9 CASPubMedWeb of Science®Google Scholar 21 Diczfalusy, E., and Lauritzen, C.: Oestrogene beim Menschen. Berlin, Springer-Verlag, 1961; pp. 279. 10.1007/978-3-642-87688-2 Google Scholar 22 Drill, V. A.: Physiology and pharmacology of steroids affecting tumor growth. In Biological Activities of Steroids in Relation to Cancer. G. Pincus, and E. P. Vollmer, eds. New York City, Academic Press, 1960; pp. 25–59. 10.1016/B978-1-4832-2866-2.50008-8 Google Scholar 23 Eik-Nes, K. B., and Hall, P. F.: Secretion of steroid hormone in vivo. Vitam. and Horm. 23: 153–208, 1965. 10.1016/S0083-6729(08)60382-9 CASPubMedGoogle Scholar 24 Elias, J. J.: Cultivation of adult mouse mammary gland in hormone-enriched synthetic medium. Science 126: 842–844, 1957. 10.1126/science.126.3278.842-a CASPubMedWeb of Science®Google Scholar 25 Engel, L. L.: Recent studies on estrogen metabolism. In Biological Activities of Steroids in Relation to Cancer, G. Pincus, and E. P. Vollmer, eds. New York City, Academic Press, 1960; pp. 111–127. 10.1016/B978-1-4832-2866-2.50012-X Google Scholar 26 Fishman, J., Hellman, L., Zumoff, B., and Gallagher, T. F.: Influence of thyroid hormone on estrogen metabolism in man. J. Clin. Endocr. 22: 389, 1962. 10.1210/jcem-22-4-389 CASPubMedWeb of Science®Google Scholar 27 Furth, J., Clifton, K. H., and Buffett, R. F.: An evaluation of pituitary and other hormonal factors in growth and development of the mammary gland and mammary tumors. In International Symposium on Mammary Cancer, L. Severi ed. Perugia, Division of Cancer Research, 1958; pp. 513–516. Google Scholar 28 Gallagher, T. F., Fishman, J., Zumoff, B., Cassouto, J., and Hellman, L.: Studies of production and metabolism of estrogens in human breast cancer. In Endogenous Factors Influencing Host-Tumor Balance, R. L. Wissler, T. Dao, and J. S. Wood eds. Chicago, Univ. of Chicago Press, 1967; pp. 127–135. Google Scholar 29 Geschickter, C. F., and Byrnes, E. W.: Factors influencing the development and time of appearance of mammary cancer in the rat in response to estrogen. Arch. Path. 33: 334–356, 1942. CASWeb of Science®Google Scholar 30 Gorski, J., Notebroom, W. D., and Nicolette, J. A.: Estrogen control of the synthesis of RNA and protein in the uterus. J. Cell. Comp. Physiol. 66: 91–110, 1965. 10.1002/jcp.1030660410 CASWeb of Science®Google Scholar 31 Hecker, E., and Farthofer, G.: Oestrogene und Antioestrogene wirkung einiger oestranabkommling in vitro in vivo. und Biochim. Biophys. Acta 71: 196–198, 1963. 10.1016/0006-3002(63)91003-5 CASWeb of Science®Google Scholar 32 Hellman, L., Fishman, J., Zumoff, B., Cassouto, J., and Gallagher, T. F.: Studies of estradiol transformation in women with breast cancer. J. Clin. Endocr. 27: 1087–1089, 1967. 10.1210/jcem-27-8-1087 CASPubMedWeb of Science®Google Scholar 33 Hisaw, F. L., Velardo, J. T., and Goolsby, C. M.: Interaction of estrogens on uterine growth. J. Clin. Endocr. 14: 1134–1143, 1954. CASPubMedWeb of Science®Google Scholar 34 Hobkirk, R., and Nilsen, M.: Urinary estrogens in non-pregnant human subjects measured by a modification of Bauld's method. Steroids 3: 453, 1964. 10.1016/0039-128X(64)90006-6 Web of Science®Google Scholar 35 Huggins, C., and Jensen, E. V.: The depression of estrone induced uterine growth by phenolic estrogens with oxygen functions at position 6 or 16; the impeded estrogens. J. Exp. Med. 102: 335–346, 1955. 10.1084/jem.102.3.335 CASPubMedWeb of Science®Google Scholar 36 Irvine, W. T., Aitken, E. H., Rendleman, D. F., and Folca, P. J.: Urinary estrogen measurements after oophorectomy and adrenalectomy for advanced breast cancer. Lancet 2: 791–6, 1961. 10.1016/S0140-6736(61)91087-X Web of Science®Google Scholar 37 Jensen, E. V., DeSombre, E. R., and Jungblut, P. W.: Estrogen receptors in hormone responsive tissues and tumors. In Endogenous Factors Influencing Host Tumor Balance, R. W. Wissler, T. L. Dao, and S. Wood, eds. Chicago, Univ. of Chicago Press, 1968; pp. 15–30. Google Scholar 38 King, R. J. B., Gordon, J., Cowan, D. M., and Inman, D. R.: The intranuclear localization of (6-73H)-oestradiol-17B in dimethylbenzanthracene induced rat mammary adenocarcinomas and other tissues. J. Endocr. 36: 139–150, 1966. 10.1677/joe.0.0360139 CASPubMedWeb of Science®Google Scholar 39 Korenman, S. G.: Radio-ligand binding assay of specific estrogens using a soluble uterine macromolecule. J. Clin. Endocr. 28: 127–130, 1968. 10.1210/jcem-28-1-127 CASPubMedWeb of Science®Google Scholar 40 Lauritzen, C.: Untersuchungen zur biologische aktivitat de oestriol-epimeren 16 epi-oestriol, 17 epioestriol, und 16,17 epi-oestriol. Acta Endocr. 45: 509–526, 1964. CASPubMedWeb of Science®Google Scholar 41 Lemon, H. M., Kravetz, P., Michelson, A. L., Lowell, F. C., and Wotiz, H. H.: Endocrine functions in bronchial asthma and hay fever. J. Allergy 29: 384–395, 1958. 10.1016/0021-8707(58)90081-9 CASPubMedWeb of Science®Google Scholar 42 Lemon, H. M., Wotiz, H. H., Parsons, L., and Mozden, P. J.: Reduced estriol excretion in patients with breast cancer prior to endocrine therapy. J. A. M. A. 196: 1128–1136, 1966. CASPubMedWeb of Science®Google Scholar 43 Lerner, L. J.: Hormone antagonists inhibitors of specific activities of estrogen and androgen. Recent Prog. Horm. Res. 20: 434, 1964. Google Scholar 44 Lilienfeld, A. M., and Johnson, E.: The age distribution in female breast and genital cancers. Cancer 8: 875–882, 1955. 10.1002/1097-0142(1955)8:5 3.0.CO;2-Z CASPubMedWeb of Science®Google Scholar 45 Loraine, J. A.: The estimation of anterior pituitary hormones in patients with mammary carcinoma. In Endocrine Aspects of Breast Cancer, A. R. Currie ed. Livingstone, Edinburgh, 1958; pp. 158–169. Google Scholar 46 MacDonald, P. C., Rombault, R. P., and Siiteri, P. K.: Plasma precursors of estrogen. I. Extent of conversion of plasma Δ4 androstenedione to estrone in normal males and non-pregnant normal, castrate, and adrenalectomized females. J. Clin. Endocr. 27: 1103–1111, 1967. 10.1210/jcem-27-8-1103 CASPubMedWeb of Science®Google Scholar 47 Mahesh, V. B.: A paper chromatographic method for estrogen determination. Steroids 3: 647–662, 1964. 10.1016/0039-128X(64)90113-8 CASWeb of Science®Google Scholar 48 Marmorsten, J., Crowley, C. G., Myers, S. M., Stern, E., and Hopkins, C. E.: Urinary excretion of neutral 17 ketosteroids and pregnanediol by patients with breast cancer and benign breast disease. Amer. J. Obstet. Gynec. 92: 447–459, 1965. Web of Science®Google Scholar 49 Marmorsten, J., Crowley, L. G., Myers, S. M., Stern, E., and Hopkins, C. E.: II. Urinary excretion of estrone, estradiol and estriol by patients with breast cancer and benign breast disease. Amer. J. Obstet. Gynec. 92: 460–467, 1965. Web of Science®Google Scholar 50 Miller, H., Durant, J. A., Jacobs, A. G., and Allison, J. F.: Alternate discriminating function for determining hormone dependency of breast cancer. Brit. Med. J. 1: 147–149, 1967. 10.1136/bmj.1.5533.147 CASPubMedWeb of Science®Google Scholar 51 Mobbs, B. G.: The uptake of tritiated oestradiol by dimethylbenzanthracene-induced mammary tumors of the rat. J. Endocr. 36: 409–414, 1966. 10.1677/joe.0.0360409 CASPubMedWeb of Science®Google Scholar 52 Ono, S.: Studies of the extragonadal estrogens. Folia Endocr. Japan. 39: 678–697, 1963. 10.1507/endocrine1927.39.8_678 CASPubMedGoogle Scholar 53 Persson, B. H., and Risholm, L.: Oophorectomy and cortisone treatment as a method of eliminating oestrogen production in patients with breast cancer. Acta Endocr. 47: 15–26, 1964. CASPubMedWeb of Science®Google Scholar 54 Pincus, G.: Steroids and tumors, Canad. Cancer Conf. 4: 29–42, 1961. CASGoogle Scholar 55 Pincus, G., Dorfman, R. I., Romanoff, L. P., Rubin, B. C., Bloch, E., Carlo, J., and Freeman, H.: Steroid metabolisms in aging men and women. Recent Prog. Horm. Res. 11: 307–334, 1955. Web of Science®Google Scholar 56 Preedy, J. R. K., and Aitken, E. H.: The determination of estrone, estradiol 17B, and estriol in urine and plasma with column partition chromatography. J. Biol. Chem. 236: 1300–1311, 1961. CASPubMedWeb of Science®Google Scholar 57 Russfield, A. B.: Combined bioassay and histological study of 73 human hypophyses. Cancer 13: 790–803, 1960. 10.1002/1097-0142(196007/08)13:4 3.0.CO;2-3 CASPubMedWeb of Science®Google Scholar 58 Salokangas, R. A. A., and Bulbrook, R. D.: The determination of small quantities of urinary oestrone, oestradiol 17B, and oestriol using Ittrich's extraction method. J. Endocr. 22: 47–58, 1961. 10.1677/joe.0.0220047 CASPubMedWeb of Science®Google Scholar 59 Sandberg, A. A., and Slaunwhite, W. R.: Studies on phenolic steroids in human subjects. VII Metabolic fate of estriol and its glucuronide. J. Clin. Invest. 44: 694–702, 1965. 10.1172/JCI105181 CASPubMedWeb of Science®Google Scholar 60 Saunders, F. J.: Effect of steroids on pituitary gonadotropin and fertility. Recent Prog. Horm. Res. 20: 395, 1964. CASPubMedWeb of Science®Google Scholar 61 Schubert, K., and Bacigalupo, G.: Steroidstoffwechsel bei mastopathie unter oestradioleinwirkung. Arch. Geschwulstforsch. 17: 207–216, 1961. CASPubMedWeb of Science®Google Scholar 62 Schubert, K.: Free and glucuronic acid bound corticosteroids in the plasma of mammary cancer patients during the I. V. infusion of ACTH-(trans.). Arch. Geschwulstforsch. 22: 209–215, 1964. Google Scholar 63 Schubert, K., and Bacigalupo, G.: Differences of steroid metabolism in breast cancer after hormone stimulation. Acta Un. Int. Cancr. 20: 1489–1492, 1964. CASPubMedWeb of Science®Google Scholar 64 Schubert, K., and Bacigalupo, G.: Metabolism and metabolic reaction after infusion of dehydroepiandrosterone phosphate in cases of mammary cancer and mastopathy. I. Conversion of dehydroepiandrosterone and formation of androsterone epiandrosterone etiocholanolone and 11-oxygenated 17 ketosteroids. Arch. Geschwulstforsch. 24: 1–9, 1964. CASGoogle Scholar 65 Schweppe, J. S., Jungman, R. A., and Lewin, I.: Urine steroid excretion in post-menopausal breast cancer. Response to corticotropin stimulation and dexamethasone suppression. Cancer 20: 155–163, 1967. 10.1002/1097-0142(1967)20:1 3.0.CO;2-S CASPubMedWeb of Science®Google Scholar 66 Sciarra, F., deFelice, M., Concolino, G., Capone, M., and Lotti, P.: Data on the estrogenic secretion of the adrenal cortex. Acta Endocr. 15: 699–702, 1962. CASPubMedGoogle Scholar 67 Shimkin, M. B.: Cancer of the breast. Some old facts and new perspectives. JAMA 183: 358, 1963. 10.1001/jama.1963.63700050028015 CASPubMedWeb of Science®Google Scholar 68 Sfikakis, A., Ikkos, D., and Marketos, S.: Increased urinary estrogen after methopyropone (SU-4885) in 2 patients with secondary amenorrhea. J. Clin. Endocr. 26: 325–328, 1966. 10.1210/jcem-26-3-325 CASPubMedWeb of Science®Google Scholar 69 Sommers, S. C.: Pituitary cell relations to body states. Lab. Invest. 8: 588–621, 1959. CASPubMedWeb of Science®Google Scholar 70 Stoa, K. F., and Thorson, T.: Urinary excretion of metabolites in patients with liver cirrhosis following intravenous administration of 17B oestradiol 414-C. (abstr.) Acta Endocr. Suppl. 119, 1967. Google Scholar 71 Strong, J. A.: The place of hormone assay in human breast cancer. In Endocrine Aspects of Breast Cancer, A. R. Currie ed. Livingstone, Edinburgh and London, 1958; pp. 141–157. Google Scholar 72 Toft, D., and Gorski, J.: A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization. Proc. Nat. Acad. Sci. U. S. 55: 1574, 1966. 10.1073/pnas.55.6.1574 CASPubMedWeb of Science®Google Scholar 73 Velardo, J. T., and Sturgis, S. H.: Interaction of 16 epi-estriol and estradiol 17B on uterine growth. Proc. Soc. Exp. Biol. Med. 90: 609, 1955. 10.3181/00379727-90-22112 CASPubMedWeb of Science®Google Scholar 74 Villee, C. A., and Hagerman, D. H.: Compounds with anti-estrogenic activit. in vitro Endocrinology 60: 552–558, 1957. 10.1210/endo-60-4-552 CASPubMedWeb of Science®Google Scholar 75 Wicks, A. E., and Segal, S. J.: Time and dose relationships in estriol-estradiol interaction. Proc. Soc. Exp. Biol. Med. 93: 270–273, 1956. 10.3181/00379727-93-22729 CASPubMedWeb of Science®Google Scholar 76 Wotiz, H. H., Charransol, G., and Smith, I. N.: Gas chromatographic measurement of plasma estrogens using an electron capture detector. Steroids 10: 127–154, 1967. 10.1016/0039-128X(67)90076-1 CASPubMedWeb of Science®Google Scholar 77 Wynder, E. L., Bross, I. J., and Hiramaya, T.: A study of the epidemiology of cancer of the breast. Cancer 13: 559–601, 1960. 10.1002/1097-0142(196005/06)13:3 3.0.CO;2-0 CASPubMedWeb of Science®Google Scholar Citing Literature Volume23, Issue4April 1969Pages 781-790 ReferencesRelatedInformation
Referência(s)